This is a preview of subscription content, log in via an institution to check access.
Reference
Goel A, et al. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. Journal of Gastroenterology and Hepatology : 4 Jun 2018
Rights and permissions
About this article
Cite this article
Generic sofosbuvir/velpatasvir cost effective for HCV in India. PharmacoEcon Outcomes News 805, 18 (2018). https://doi.org/10.1007/s40274-018-5020-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5020-1